

3 September 2021

ASX ANNOUNCEMENT – Results of Special Meeting of Stockholders

Minnesota, United States and Melbourne, Australia – 3 September 2021 – Osprey Medical Inc. (ASX: OSP) held a Special Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Special Meeting and Proxy Statement dated 20 August 2021 were passed by way of a poll.

As a result of Resolution 2 passing, the charter amendment to effect a reverse stock split will proceed. Stockholders are directed to the ASX announcements of 20 August 2021 and today's date which set out the timetable for this reverse stock split (consolidation). The Company particularly directs stockholders' attention to the last day of trading on a pre-consolidation basis of 14 September 2021.

This release dated 3 September 2021 has been authorised for lodgement to ASX by Mike McCormick, CEO of Osprey Medical.

– ENDS –

Contact details:

Osprey Medical

Doug Schoenberg

VP of Marketing

T: +1 (952) 955 8230

dschoenberg@ospreymed.com

Investor Relations

Prash Jitendran

Vesparum Capital

T: +61 3 8582 4800

ospreymed@vesparum.com

Media Relations

Ciara Byrne

Mana Communications

T: +61 41 3519 430

cbyrne@manacommunications.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and

unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

SPECIAL MEETING (COMMON STOCK)

Friday, 3 September 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolutions voted on at the Meeting			Proxy Votes (as at Proxy Close)				Poll (Manner in which votes were cast in person or by proxy (where applicable) on a Poll at the Meeting)			
No.	Short Description	Strike Y/N/NA	For	Against	Discretionary (Open Votes)	Abstain	For	Against	Abstain	Result
1A	RE-ELECTION OF MR STEVEN BRANDT AS A CLASS II DIRECTOR	NA	889,851,093 100.00%	0 0.00%	0 0.00%	496,996	889,851,093 100.00%	0 0.00%	496,996	Carried
1B	RE-ELECTION OF MR MARTIN EMERSON AS A CLASS II DIRECTOR	NA	889,851,093 100.00%	0 0.00%	0 0.00%	496,996	889,851,093 100.00%	0 0.00%	496,996	Carried
2	APPROVAL OF CHARTER AMENDMENT TO EFFECT REVERSE STOCK SPLIT	NA	878,862,134 99.17%	7,327,997 0.83%	0 0.00%	10,138,928	878,862,134 99.17%	7,327,997 0.83%	10,138,928	Carried
3A	APPROVAL OF GRANT OF OPTIONS TO NON-EXECUTIVE DIRECTOR MR STEVEN BRANDT	NA	849,118,806 94.81%	46,489,753 5.19%	0 0.00%	710,000	849,118,806 94.81%	46,489,753 5.19%	710,000	Carried
3B	APPROVAL OF GRANT OF OPTIONS TO NON-EXECUTIVE DIRECTOR MR MARTIN EMERSON	NA	849,118,806 94.81%	46,489,753 5.19%	0 0.00%	710,000	849,118,806 94.81%	46,489,753 5.19%	710,000	Carried